NCT04216589View on ClinicalTrials.gov

Study of Semaglutide for Non-Alcoholic Fatty Liver Disease (NAFLD), a Metabolic Syndrome With Insulin Resistance, Increased Hepatic Lipids, and Increased Cardiovascular Disease Risk (The SLIM LIVER Study)

PHASE2CompletedINTERVENTIONAL
Enrollment

51

Participants

Timeline

Start Date

February 19, 2021

Primary Completion Date

March 16, 2023

Study Completion Date

September 15, 2023

Conditions
HIV InfectionsNon-Alcoholic Fatty Liver Disease
Interventions
DRUG

Semaglutide

Administered subcutaneously

Trial Locations (9)

21287

Johns Hopkins University CRS, Baltimore

35294

Alabama CRS (Site ID: 31788), Birmingham

43210

Ohio State University CRS (Site ID: 2301), Columbus

77009

Houston AIDS Research Team CRS (Site ID: 31473), Houston

80045

University of Colorado Hospital CRS (Site ID: 6101), Aurora

02114

Massachusetts General Hospital CRS (MGH CRS) (Site ID: 101), Boston

45267-0405

Cincinnati Clinical Research Site (Site ID: 2401), Cincinnati

98104-9929

University of Washington AIDS CRS (Site ID: 1401), Seattle

21040-360

Instituto de Pesquisa Clinica Evandro Chagas (IPEC) CRS (Site ID: 12101), Rio de Janeiro

All Listed Sponsors
collaborator

The University of Texas Health Science Center, Houston

OTHER

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT04216589 - Study of Semaglutide for Non-Alcoholic Fatty Liver Disease (NAFLD), a Metabolic Syndrome With Insulin Resistance, Increased Hepatic Lipids, and Increased Cardiovascular Disease Risk (The SLIM LIVER Study) | Biotech Hunter | Biotech Hunter